DAEWOONG PHARMA Logo

DAEWOONG PHARMA

A global R&D partner for drug development, manufacturing, and commercialization services.

069620 | KO

Overview

Corporate Details

ISIN(s):
KR7069620003
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 제약공단4길 35-14, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Daewoong Pharmaceutical is a research and development-oriented pharmaceutical company established in 1945. The company manufactures and sells a range of healthcare products, including prescription drugs, over-the-counter medicines, and active pharmaceutical ingredients (APIs). A core component of its strategy is an "Open Collaboration" model, through which it partners with academic and industry collaborators globally to develop innovative, first-in-class drugs. Daewoong provides comprehensive support to its partners, including R&D investment, access to GMP-certified manufacturing facilities for biologics like stem cells, clinical trial support, and formulation services, from initial idea validation through to commercialization.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Regulatory News Service
투자판단관련주요경영사항
Korean 14.2 KB
2025-09-05 00:00
Regulatory News Service
투자판단관련주요경영사항
Korean 8.3 KB
2025-08-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.5 KB
2025-08-18 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 37.1 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 4.1 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 6.5 MB
2025-07-31 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.2 KB
2025-07-30 00:00
Regulatory News Service
투자판단관련주요경영사항
Korean 8.8 KB
2025-07-03 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 101.6 KB
2025-06-30 00:00
Environmental & Social Information
지속가능경영보고서등관련사항(자율공시)
Korean 9.8 KB
2025-06-02 00:00
Governance Information
기업지배구조보고서공시
Korean 743.9 KB
2025-05-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.0 KB
2025-05-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 169.8 KB
2025-05-16 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 40.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 2.3 MB

Automate Your Workflow. Get a real-time feed of all DAEWOONG PHARMA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DAEWOONG PHARMA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DAEWOONG PHARMA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.